Milena Santos

Milena Santos

Auto-generated profile, based on publicly available information

Milena Santos

Instituto Nacional de Cardiologia -INC, Rio de Janeiro, RJ, Brasil

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Genetics and Molecular Research
Verified
Journal Article
Open access
ESE. Stur
E. Stur
LAL.P. Agostini
L.P. Agostini
FGF.M. Garcia
F.M. Garcia
GPG.T. Peterle
G.T. Peterle
LML.L. Maia
L.L. Maia
ILIuri Drumond Louro
Iuri Drumond Louro
The aims of this study were to analyze the polymorphisms XRCC1 Arg194Trp, XRCC1 Arg399Gln, XRCC3 Thr241Met, XPC Lys939Gln, ERCC1 Asn118Asn, and RAD51 -98G>C and to verify their influence on radiotherapy response and prognosis of patients with head and neck squamous cell carcinoma (HNSCC). Peripheral blood DNA was extracted from 311 patients and analyzed by PCR-RFLP. Our results showed that in irradiated oral and oropharyngeal patients, the 939Gln allele increased 6-fold local disease relapse risk (OR = 6.04; CI = 1.47-24.88) and over 2-fold the earliness of relapse (HR = 2.63; CI = 1.04-6.70). As for the XRCC3 polymorphism, multivariate analysis showed that the 241Met allele increases over 33-fold local relapse risk (OR = 33.64; CI = 3.23-350.85), over 12-fold earliness of relapse (HR = 12.55; CI = 2.47-63.73) and over 3-fold earliness of death (HR = 3.04; CI = 1.08-8.61). For polymorphism RAD51 -98, multivariate analysis showed that allele C increases over 3-fold the risk of relapse (OR = 3.13; CI = 1.12-8.78) and over 2-fold the earliness of relapse (HR = 2.84; CI = 1.25-6.47). For polymorphism XRCC1 Arg399Gln, multivariate analysis showed that the 399Gln allele increased the risk of local disease relapse for irradiated oral and oropharyngeal patients (OR = 3.35; CI = 1.10-10.13) by over 3-fold. Based on these results, we suggest that these polymorphisms may be useful markers of prognosis in HNSCC.

18 August 2025 in OnScience
Verified
Journal Article
Open access
PDF file
EBErika Pires Ribeiro Bernardo
Erika Pires Ribeiro Bernardo
NHNatália Da Costa Hipólito
Natália Da Costa Hipólito
WMWolney De Andrade Martins
Wolney De Andrade Martins
MFMilena Rego dos Santos Espelta de Faria
Milena Rego dos Santos Espelta de Faria
CMClaudio Tinoco Mesquita
Claudio Tinoco Mesquita
PBPedro Ribeiro Bernardo
Pedro Ribeiro Bernardo
O mieloma múltiplo (MM) é uma neoplasia maligna de células B caracterizada pela proliferação clonal de plasmócitos produtores de imunoglobulinas monoclonais. A amiloidose por cadeias leves (AL) é a forma mais comum de amiloidose sistêmica com acometimento cardíaco, associada ao MM em proporção significativa dos casos. O envolvimento cardíaco usualmente cursa com disfunção diastólica e fração de ejeção preservada, porém casos atípicos com disfunção sistólica grave são descritos, representando desafio diagnóstico e terapêutico. Relatamos caso de paciente com MM, insuficiência renal e insuficiência cardíaca com fração de ejeção reduzida, confirmado diagnóstico presuntivo de amiloidose cardíaca AL por biópsia de gordura abdominal positiva e exclusão de amiloidose por transtirretina (ATTR) por cintilografia com pirofosfato. Destacamos a importância da ecocardiografia com strain bidimensional (2D-STI) e da ressonância magnética cardíaca (RMC) no diagnóstico precoce. A integração de métodos clínicos, laboratoriais e imagiológicos é essencial para manejo adequado, especialmente na ausência de espectrometria de massa. O reconhecimento precoce permite intervenção terapêutica e melhora do prognóstico.

18 December 2022 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Open access
PDF file
AIAurora Felice Castro Issa
Aurora Felice Castro Issa
TGTereza Cristina Felippe Guimarães
Tereza Cristina Felippe Guimarães
VVVithoria Vidotti
Vithoria Vidotti
GZGabriela Zagni
Gabriela Zagni
MSMilena Santos
Milena Santos
JMJacqueline Miranda
Jacqueline Miranda
We report 3 cases of heart transplantation in adults due to chemotherapy-induced cardiotoxicity in a transplant center in Rio de Janeiro, Brazil. All patients received anthracyclines during cancer treatment. We reviewed and discussed the cases with data from the literature, addressing the importance of early diagnosis and treatment of heart failure in cancer survivors. Heart Transplantation in Patients with Chemotherapy-Induced Cardiotoxicity Abstract We report 3 cases of heart transplantation in adults due to chemotherapy-induced cardiotoxicity in a transplant center in Rio de Janeiro, Brazil. All patients received anthracyclines during cancer treatment. We reviewed and discussed the cases with data from the literature, addressing the importance of early diagnosis and treatment of heart failure in cancer survivors. Heart Transplantation in Patients with Chemotherapy-Induced Cardiotoxicity

18 December 2022 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Open access
PDF file
AIAurora Felice Castro Issa
Aurora Felice Castro Issa
GZGabriela Zagni
Gabriela Zagni
VVVithoria Vidotti
Vithoria Vidotti
TGTereza Cristina Felippe Guimarães
Tereza Cristina Felippe Guimarães
MSMilena Rego dos Santos
Milena Rego dos Santos
CSCarolina Maria Pinto Domingues Carvalho Silva
Carolina Maria Pinto Domingues Carvalho Silva
During cancer treatment, surgery may be indicated for patients with diverse purposes, such as diagnosis, staging, oncologic cure, palliative treatment, support, or restorative treatment. Oncologic surgery may be conducted as an initial cancer treatment or after conducting treatments such as chemotherapy or radiotherapy, thus underscoring the cardiotoxic potential of different cancer therapies. In patients undergoing non-cardiac surgeries, the prevalence of comorbidities, the clinical condition before surgery, and factors inherent to the surgical procedure, such as urgency, magnitude, type, and duration, [...] During cancer treatment, surgery may be indicated for patients with diverse purposes, such as diagnosis, staging, oncologic cure, palliative treatment, support, or restorative treatment. Oncologic surgery may be conducted as an initial cancer treatment or after conducting treatments such as chemotherapy or radiotherapy, thus underscoring the cardiotoxic potential of different cancer therapies. In patients undergoing non-cardiac surgeries, the prevalence of comorbidities, the clinical condition before surgery, and factors inherent to the surgical procedure, such as urgency, magnitude, type, and duration,